FindTrial
Sign In

Study of patients admitted with aluminium phosphide poisoning

Retrospective multicentre study of patients admitted with Aluminium phosphide poisoning from India (REMAP-INDIA) - REMAP-INDIA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105698
Enrollment
160
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T571- Toxic effect of phosphorus and itscompounds

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Dr Amarja Havaldar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients admitted with diagnosis of aluminium phosphide poisoning will be included in the study.

Exclusion criteria

Exclusion criteria: Patients admitted with diagnosis apart from aluminium phosphide poisoning will be excluded.

Design outcomes

Primary

MeasureTime frame
To compare the mortality among patients who received ECMO or extracorporeal therapies vs standard of care.Timepoint: evaluated at 4 weeks—

Secondary

MeasureTime frame
To study the cost effectiveness of ECMO or extracorporeal therapies vs standard of careTimepoint: Till 4 weeks—

Countries

India

Contacts

Public ContactDr Amarja Havaldar

St Johns medical college Bangalore

amarjahavalar2009@gmail.com9036082112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026